

Japan

Population 2018

127 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	18 (15–21)	14 (12–16)
HIV-positive TB incidence	0.1 (0.031–0.21)	0.08 (0.02–0.17)
MDR/RR-TB incidence ^{oo}	0.51 (0.22–0.93)	0.4 (0.17–0.73)
HIV-negative TB mortality	2.8 (2.6–2.9)	2.2 (2.1–2.3)
HIV-positive TB mortality	0.016 (<0.01–0.034)	0.01 (0–0.03)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	2.3%
Previously treated cases	11% (6.1–17)

TB case notifications, 2018

Total new and relapse	15 590
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	8%
- % pulmonary	77%
- % bacteriologically confirmed ^{ooo}	86%
- % children aged 0–14 years	1%
- % women	40%
- % men	59%
Total cases notified	15 590

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	16% (13–18)

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	44	3%
- on antiretroviral therapy		

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	74%
- Previously treated cases	67%
Laboratory-confirmed cases*	MDR/RR-TB: 94, XDR-TB: 59
Patients started on treatment**	MDR/RR-TB: 59, XDR-TB: 56
MDR/RR-TB cases tested for resistance to second-line drugs	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2017	68%	16 702
Previously treated cases, excluding relapse, registered in 2017		
HIV-positive TB cases registered in 2017	65%	31
MDR/RR-TB cases started on second-line treatment in 2016	52%	56
XDR-TB cases started on second-line treatment in 2016		

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	62% (46–96)

TB financing, 2019

National TB budget (US\$ millions)

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Total TB incidence
— New and relapse TB cases notified
— HIV-positive TB incidence

(Rate per 100 000 population per year)




— HIV-negative TB mortality

Notified cases by age group and sex, 2018



■ Females ■ Males □ Incidence

Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB